Wall Street expects a year-over-year increase in earnings on higher revenues when Revvity (RVTY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 31, 2025, might help the stock move higher if these key numbers are better than expe ...

Company Overview - Revvity has a market capitalization of $13.86 billion with an earnings yield of 4.4%, which is favorable compared to the industry's 3.7% [1] - The company delivered an earnings surprise of 13.3% in the last reported quarter [1] FDA Approval and Product Development - Revvity received FDA 510(k) clearance for EUROIMMUN's automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone, making it the only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma [2] - The assay is processed on Revvity's random-access iSYS or i10 instruments, offering quick turnaround times, high-throughput testing, minimal technician training, and high accuracy [4] - The assay is expected to enhance diagnostic capabilities for conditions like hypogonadism and impotence by providing direct measurement of free testosterone levels in a single test [4] - Management believes the FDA clearance will expand the FDA-cleared menu for EUROIMMUN's ChLIA automation solutions, serving a diverse patient pool across all demographics [5] - Results on EUROIMMUN's ChLIA platforms are expected to be rapidly available, with the first result available in 48 minutes and an estimated throughput of nearly 60 tests per hour [15] Market and Industry Prospects - The global testosterone test market was valued at $100 million in 2023 and is anticipated to reach $208.1 million by 2034, growing at a CAGR of 6.9% [6] - Factors driving the market include rising awareness about hormonal disorders and increasing prevalence of male infertility [6] - The latest FDA clearance is expected to be a significant milestone for Revvity, boosting its business in this growing market [6] Recent Developments - In November 2024, Revvity expanded its collaboration with Genomics England to advance critical genomic initiatives across the UK [7] - The company reported solid revenue growth in its third-quarter 2024 results, both on a reported and organic basis [7] Stock Performance - Following the FDA approval announcement, Revvity's shares lost nearly 2.2% by Friday's closing [3] - Historically, the company has gained a top-line boost from regulatory achievements and product launches, but the stock declined overall despite the latest FDA approval [3] - Over the past year, Revvity's shares have gained 2.8%, outperforming the industry's 9.8% decline, while the S&P 500 gained 23% [9] Comparison with Industry Peers - Cardinal Health (CAH) has a Zacks Rank 2 (Buy) with an estimated long-term growth rate of 10.5% and an average earnings surprise of 11.2% over the trailing four quarters [11] - ResMed (RMD) has a Zacks Rank 2 with an estimated long-term growth rate of 14.8% and an average earnings surprise of 6.4% over the trailing four quarters [12] - Boston Scientific (BSX) has a Zacks Rank 2 with an estimated long-term growth rate of 13.8% and an average earnings surprise of 8.3% over the trailing four quarters [12] - Cardinal Health's shares have gained 14.9% compared to the industry's 2.1% growth, ResMed has gained 34.5% compared to the industry's 7.8% growth, and Boston Scientific has rallied 58.3% compared to the industry's 7.8% growth over the past year [11][12][13]

Revvity, Inc. (NYSE: RVTY ) is clearly a leader in life sciences and diagnostics. Both of these revenue verticals provide cutting-edge tools and platforms for drug discovery and development, as well as early detection of genetic and infectious conditions. The company has a globalMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, U ...

It has been about a month since the last earnings report for Revvity (RVTY) . Shares have lost about 8.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Revvity due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. RVTY Q3 Earnings & Revenues Beat Estimates, Guidance R ...

Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday.The company posted quarterly earnings of $1.28 per share which beat the analyst consensus estimate of $1.13 per share. The company reported quarterly sales of $684.05 million which beat the analyst consensus estimate of $679.65 million.Revvity also authorized a new $1 billion share repurchase program.“We performed well during the third quarter with a return to positive revenue growth, strong margins, and another period of exce ...

Revvity, Inc. (RVTY) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.28, which beat the Zacks Consensus Estimate of $1.13 by 13.3%. The bottom line improved 8.5% from the year-ago quarter’s level.GAAP EPS from continuing operations was 76 cents compared with 26 cents in the prior-year period. However, GAAP EPS in the reported quarter was 77 cents, which includes a loss of 1 cent per share from discontinued operations.Revenue DetailsBased in Waltham, MA, this leading MedTech company repor ...

Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.27%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.13 per share when it actually produced earnings of $1.22, delivering a surprise of 7.96%.Over the last four quarter ...

Core Viewpoint - Revvity, Inc. has launched the EURORealTime APOE assay in European countries with CE mark approval, which is expected to enhance the company's position in the Alzheimer's disease treatment market by enabling accurate genotyping of the APOE gene [1][2]. Company Developments - The EURORealTime APOE PCR test allows for the simultaneous detection of the three most common APOE forms (E2, E3, E4) from a single blood sample, streamlining the genotyping process [3]. - The assay can be automated on Revvity's instruments, including the EUROIMMUN PreNAT II and chemagic 360 platforms, facilitating scalability in processing [3]. - Revvity's management is optimistic about the ongoing strong execution in its Diagnostics segment, which has shown slight revenue improvement in the second quarter of 2024 [7]. Industry Prospects - The global Alzheimer's therapeutics market was valued at $4.05 billion in 2022 and is projected to grow at a CAGR of approximately 19.9% from 2023 to 2030, driven by the rising prevalence of Alzheimer's disease and demand for effective treatments [6]. - The launch of the APOE assay is expected to significantly boost Revvity's business within this growing market [6]. Competitive Landscape - Eli Lilly's Kisunla (donanemab-azbt) received approval in Japan and the FDA for treating early symptomatic Alzheimer's, indicating strong competition in the Alzheimer's treatment space [8][9]. - Biogen, in collaboration with Eisai, has also made significant advancements with the approval of Leqembi for Alzheimer's treatment in Great Britain and the UAE, further intensifying competition [10][11]. - Intra-Cellular Therapies is actively enrolling patients in Phase 2 studies for treatments related to Alzheimer's, showcasing ongoing innovation in the industry [12][13].

Core Viewpoint - Revvity, Inc. (RVTY) is positioned for growth due to its strong product portfolio and focus on artificial intelligence (AI), despite facing challenges from foreign exchange volatility and integration risks [1][8][9] Company Performance - RVTY's shares have increased by 13.4% year to date, outperforming the industry growth of 0.7% and the S&P 500's increase of 20.8% during the same period [2] - The company has a market capitalization of $15.29 billion and projects a growth rate of 7.6% over the next five years [3] - RVTY's earnings have exceeded the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 5.02% [3] Product Development - The company has introduced several AI-driven solutions, including the PKeye Workflow Monitor and Signals Research Suite, enhancing its product offerings [3][4] - RVTY's software and informatics segment, particularly the Signals Software, has shown rapid growth, with three new SaaS-based solutions launched in the recent quarter [5] - The launch of a next-generation sequencing solution for Newborn Screening is expected to strengthen RVTY's market leadership [6] Financial Outlook - RVTY's diagnostic businesses have remained robust, with the immunodiagnostics franchise growing in the low double-digits [7] - The Zacks Consensus Estimate for third-quarter 2024 revenues is $678.2 million, reflecting a 1.1% increase from the previous year, while the EPS estimate is $1.13, indicating a year-over-year decline of 4.2% [10]

Core Viewpoint - Revvity, Inc. (RVTY) is positioned for growth due to its strong product portfolio and focus on artificial intelligence (AI), despite facing challenges from foreign exchange volatility and integration risks [1] Company Performance - Revvity's shares have increased by 9.1% year to date, outperforming the industry growth of 0.6% and the S&P 500's increase of 15% during the same period [2] - The company has a market capitalization of $14.51 billion and projects an 8.9% growth over the next five years, with earnings surpassing the Zacks Consensus Estimate in three of the last four quarters, averaging a surprise of 5.02% [3] Product and Innovation - The company is optimistic about its AI initiatives, including the introduction of PKeye Workflow Monitor and Signals Research Suite, which enhance laboratory management and data aggregation [5][6] - Revvity's software and informatics division, particularly the Signals Software, has shown strong growth, supported by the launch of three new SaaS-based offerings [6] - The launch of a next-generation sequencing solution for Newborn Screening is expected to help maintain market leadership, while the expansion of GMP reagent capacity is anticipated to generate additional revenue [7] Financial Outlook - Revvity's diagnostic businesses have remained robust, with the immunodiagnostics franchise growing in the low double-digits, and an expected rise in pharma and biotech spending may boost sales in the latter half of 2024 [8] - The Zacks Consensus Estimate for earnings per share (EPS) for 2024 has increased by 2.2% to $4.75, with second-quarter 2024 revenue estimates at $678.2 million, reflecting a 1.1% improvement year-over-year [11]